StockData
Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc. (ALLO) stock

ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 3/30
$0.74−0.06 (-7.79%)

Close on Nov 17, 2026Market cap $257.08MP/E –Yield 0.00%

Allogene Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Allogene Therapeutics's price to book ratio was 0.7× on Nov 11, 2026, against 1.0× a year earlier. Over the last 5 years it ranged from 0.6× to 2.4×, with a median of 1.2×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.7×−0.3
2025Dec 31, 20251.0×+0.0
2024Dec 31, 20241.0×+0.0
2023Dec 29, 20230.9×−0.3
2022Dec 30, 20221.2×−1.0
2021Dec 31, 20212.2×−1.0
2020Dec 31, 20203.2×−2.0
2019Dec 31, 20195.1×–

More Allogene Therapeutics figures

See a number that looks wrong?